XENE
SinkerXenon Pharmaceuticals Inc. · Healthcare · Canada · $3.4B cap · $59.5M/day traded
$40.99 -2.6% · close 12 Nov · scored 13 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 13 Nov 2026, the MoatMap Score for Xenon Pharmaceuticals Inc. (XENE) is 12/100, ranked against 25,000+ stocks in 38 markets (Quality 25, Value 25, Momentum 36, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT XENON PHARMACEUTICALS INC.
Read
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for neurological disorders, with a primary emphasis on epilepsy. The company's lead candidate, azetukalner, is a novel potassium channel opener designed to treat focal onset seizures. Xenon's competitive advantage lies in its deep expertise in ion channel biology and a robust pipeline of precision medicines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.4M | 0 | 0 | 7.5M | -7.4% | — | 1.3M | 28.9M | 96.3% |
| EPS | -2.06 | -2.73 | -3.01 | -4.36 | — | -4.74 | -4.63 | -4.70 | — |
| Shares | 62.6M | 75.4M | 76.4M | 80.0M | +27.8% | 96.8M | — | — | — |
| Debt | 10.4M | 10.9M | 9.0M | 7.9M | -8.7% | 6.4M | — | — | — |
| Equity | 721.5M | 927.9M | 754.9M | 581.8M | -6.9% | — | — | — | — |
| Op CF | -101.0M | -151.1M | -181.4M | -279.1M | — | -337.5M | — | — | — |
| Inv CF | -293.4M | -111.4M | 165.0M | 218.0M | — | — | — | — | — |
| Fin CF | 278.5M | 353.5M | 12.1M | 117.1M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 81% of stocks we rank over the past year (volatility 68% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XENE are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc.(you) | $3.4B | 12 |
| ABCL | AbCellera Biologics Inc. | $3.8B | 30 |
| EPRX | Eupraxia Pharmaceuticals Inc. | $454M | 23 |
| HELP | Cybin D/B/A Helus Pharma | $744M | 38 |
| MSCL.TO | Satellos Bioscience Inc. | $138M | 12 |
| NGEN | NervGen Pharma Corp. | $154M | 4 |
| ENGN | enGene Therapeutics Inc. | $105M | 13 |
| BETR.CN | BetterLife Pharma Inc. | $99M | 23 |
| OBI.L | Ondine Biomedical Inc. | $73M | 5 |
| PMN | ProMIS Neurosciences, Inc. | $75M | 3 |
Peer medians: ROE -27.0% · P/E 19.0x · Gross margin 51.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.